TDACW Translational Development Acquisition Corp.

Price Chart

Executive Summary

Translational Development Acquisition Corp. (TDAC) has filed the definitive merger agreement and supporting documents (Registration Rights Agreement, investor presentation) for its business combination with Prologium Holding Inc., a solid-state battery developer. The deal values Prologium at a pre-money enterprise value of $3.8 billion, with a target of approximately $300 million in gross proceeds from TDAC's trust cash and a PIPE investment, subject to a $250 million minimum cash condition. This filing confirms the deal structure and terms previously announced on May 27, 2026, with no material changes.

Key Financial Metrics

Actionable Insight

Key Facts

• Prologium is valued at a pre-money enterprise value of $3.8 billion (Equity Value of $3.9 billion, adjusted for $100 million net cash).
• Targeting ~$300 million in gross proceeds from SPAC trust cash and PIPE investment.
• Minimum cash condition of $250 million (Available Cash must be >= Minimum Cash).
• Transaction structured as a two-step merger with Prologium becoming the publicly listed entity.
• TDAC had at least $172.5 million in trust as of the agreement date.
• Prologium has aggregate net cash of $100 million and no Indebtedness as of the date hereof.
• Founder to receive IP compensation shares of up to 2.5% of fully diluted share capital post-closing.
• New equity incentive plan approved with pool up to 12.5% of fully diluted share capital.
• Post-closing board to consist of 9 directors, with TDAC/Sponsor designating one director.
• Registration Rights Agreement grants holders shelf registration and up to 2 underwritten takedowns per year.
• Lock-up agreements are in place for certain shareholders.
• Transaction expected to close in H2 2026, subject to shareholder approvals, SEC effectiveness, and other customary conditions.
• Prologium has been producing cells since 2013 and shipped over 800,000 cells from its gigafactory since 2024.
• Prologium has over 1,000 patents (YE 2025) and has raised ~$690 million to date.
• French government subsidy of up to ~€1.4 billion for the Dunkirk gigafactory.
• Prologium's Gen 4 technology claims zero thermal runaway risk, energy density of 360-470 Wh/kg, and fast charging (6.4 min 5-80% SoC).

Financial Impact

Prologium valued at $3.8B pre-money enterprise value; targeting ~$300M gross proceeds; pro forma enterprise value ~$3.877B; pro forma equity value ~$4.247B at $10/share.

Risk Factors

• Shareholder redemptions could reduce available cash below the $250M minimum cash condition, jeopardizing the deal.
• PIPE investment may not fully close, reducing proceeds to Prologium's balance sheet.
• SEC review of the F-4 registration statement could delay the shareholder vote and closing.
• Execution risk in scaling manufacturing from pilot to gigafactory levels (0.5 GWh to 4+ GWh).
• Competition from other solid-state battery developers and established Li-ion manufacturers.
• Geopolitical risks related to Taiwan and supply chain dependencies.
• Potential tariff impacts on cross-border manufacturing and materials sourcing.

Market Snapshot

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

US Market Status

Related Tickers